Highlights 2017

- Installed base of close to **650 Idylla™ instruments** and commercial cartridge volume **71,000 cartridges**
- Covering over **70 countries** worldwide
- **Commercial product revenue** + 124% to **EUR 12.7m**
- **EUR 112.8m** year-end **cash position**
- Expansion of **partnership** collaborations with **pharmaceutical companies** Merck KGaA, Amgen, launch of three **new breast cancer partnerships** with A*STAR, LifeArc and Genomic Health
- Launch **Companion Diagnostics** (CDx) activities, incl. partnership with Amgen signed to register the Idylla™ RAS biomarker tests with the US FDA as a CDx test for Amgen's drug vectibix ©.
- **US commercialization launched**
- **318 employees**, 21 nationalities and balanced gender diversity 50% men and 50% women

BCART

Listed on Euronext Brussels since April 2015, ticker BCART

Commercialising an unique proprietary MDx platform Idylla™

Headquartered in Belgium (Mechelen)

Focused on oncology and infectious diseases

Founded in 2007, Biocartis provides innovative diagnostic solutions aimed at fast, accurate and globally accessible high precision diagnostics, allowing rapid and effective treatment selection and treatment progress monitoring. This brings clear benefits for the patient, the clinician, the payers, the healthcare industry and society.

Biocartis' proprietary molecular diagnostics (MDx) Idylla™ platform, launched in September 2014, is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.

Idylla™ addresses the growing demand for personalized medicine. Biocartis is focused on developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology (focus area) and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide.

End of 2017, Biocartis had fourteen oncology tests and two infectious disease tests on the market.

The unravelling of the human genome in the 2000's has led to the discovery of molecular information called biomarkers, which can be detected by molecular diagnostics (MDx), based on patient samples such as blood, urine, sputum, saliva or tissue such as tumor tissue. Having this detailed information paves the way to personalized medicine versus the 'one drug fits all' paradigm we know today, as this can be used to identify the exact type or stage of a disease, and treatment response.

Today, MDx testing is technically complex and often centralized in large, specialised molecular laboratories. Smaller hospitals or laboratories typically send out their samples for analysis by external reference centers. This is time-consuming and requires highly trained personnel. Biocartis believes in rapid and highly accurate diagnostic information near the patient, globally accessible to all, as this potentially can save lives.

High precision diagnostics for high precision medicine in a sustainable healthcare ecosystem

Fast, early and accurate diagnoses are leading the way to appropriate and cost effective care. Biocartis aims to increase its impact by creating better access to personalised molecular diagnostic testing to allow early detection, appropriate treatments and treatment monitoring for all patients.

Biocartis believes that its approach will create long-term positive impact for all stakeholders in the sustainable healthcare ecosystem, including patients, care providers, payers, industry and society as a whole. Biocartis' goal is to improve clinical practice and ultimately, contribute to better patient outcome.

Step 1: The patient sample information is entered via the console by scanning the barcode on the sample container, or by manual entry of the patient sample identification code.

Step 2: The patient sample is linked to the cartridge by scanning the barcode of the cartridge. The console automatically recognizes which test the user intends to perform.

Step 3: The patient sample is added into the cartridge. By closing the lid, the cartridge is hermetically sealed to prevent contamination of the instrument or laboratory.

Step 4: The cartridge is inserted into one of the available instruments, which will subsequently execute the appropriate test protocol. After completion of the test, results are displayed on the console.

Biocartis share

Average daily value 2017:	10.70€
Total traded volume 2017:	19,688,660

Menu of diagnostic tests

	Test	Development[1]	RUO[2]	Validation[3]	CE[4]	PMA[5]	CDx[6]	Disclosed partnerships
CRC	KRAS		✓		✓	Submission 2018E[7]		• Amgen
	NRAS-BRAF		✓		✓	Submission 2018E[7]		• Amgen
	NRAS		✓		✓			
	ctKRAS		✓		✓			• Merck
	ctNRAS-BRAF		✓		✓			• Merck
	MSI	2018E						
Lung	EGFR		✓		✓			
	ctEGFR	2018E		2019E				
	BRAF		✓	2018E				
	GeneFusion	2019E						
	NGS Prep Panel Lung	2019E						
Mel.	BRAF		✓		✓			
	ctBRAF		✓					
Breast	Therapy selection	2019E						• A*Star
	Oncotype DX®	2019E						• Genomic Health
	Resistance monitoring	2018E						• LifeArc
CDx	Novel compound Undisclosed CDx							• Amgen • Undisclosed partner

completed | ongoing | = solid biopsy | = liquid biopsy

1. Generally includes analytical validation. 2. Research Use Only 3. Clinical validation. 4. CE-IVD. 5. Premarket approval process with US FDA. 6. Companion Diagnostic. 7. Submission of the Idylla™ RAS PMA (Pre-Market Approval) documentation with the US FDA around year-end, subject to feedback from US FDA interactions. Note: launch dates are indicative. Overview is subject to change in amongst others prioritization of test development by Biocartis and/or partners driven by commercial, partnering and operational considerations

Infectious disease menu - on market tests:

- Idylla™ IFV-RSV Panel (CE-IVD, RUO1 and 510k)
- Ebola (EUA)

Sepsis host response partnership with Immunexpress, aimed at development and commercialization of Immunexpress' SeptiCyte™ test for use on Idylla™

Further menu expansion with focus on syndromic panels & bloodstream infections tests that are to be (co-)developed and commercialized through partnerships

Board of Directors

Christian Reinaudo, Chairman

Luc Gijssens

Leo Steenbergen

Ann-Christine Sundell

Harry Glorikian

Hilde Windels

Roald Borré

Peter Piot

Herman Verrelst

Executive management

Herman Verrelst, Chief Executive Officer

Ewoud Welten, Chief Financial Officer

Hilde Eylenbosch, Chief Commercial Officer

Benoit Devogelaere, Chief Technology Officer

Financial summary 2017

Key figures (EUR 1,000)	2017	2016	% Change
Total operating income	23,110	13,772	68%
Cost of sales	-8,673	-5,701	52%
Research and development expenses	-39,594	-42,091	-6%
Marketing and distribution expenses	-11,600	-10,324	12%
General and administrative expenses	-6,832	-5,827	17%
Operating expenses	-66,699	-63,943	4%
Operational result	-43,589	-50,171	-13%
Net financial result	-1,736	-586	196%
Income tax	3,365	980	243%
Net result	-41,960	-49,777	-16%
Cash flow from operating activities	-41,405	-53,312	-22%
Cash flow from investing activities	-4,320	-9,342	-54%
Cash flow from financing activities	75,256	41,804	80%
Net cash flow	29,531	-20,850	-242%
Cash and cash equivalents[1]	112,765	83,247	35%
Financial debt	35,388	31,407	13%

[1] Including EUR 1.2m of restricted cash (as a guarantee for KBC lease financing)

Operating income (EUR 1,000)	2017	2016	% Change
Collaboration revenue	7,739	5,278	47%
Idylla™ System sales	4,620	2,752	68%
Idylla™ Cartridge sales	8,316	4,015	107%
Product sales revenue	12,936	6,767	91%
Service revenue	282	53	432%
Total revenue	20,957	12,098	73%
Grants and other income	2,153	1,674	29%
Total operating income	23,110	13,772	68%

Product sales revenue by type (EUR 1,000)	2017	2016	% Change
Commercial revenue	12,748	5,691	124%
Research & Development revenue	187	1,076	-83%
Total product sales revenue	12,936	6,767	91%

Diversified shareholders base



Per May 2018

Contact

Investor Relations Biocartis

ir@biocartis.com

tel. +32 15 63 17 29